# Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

> **NCT02251067** · PHASE2 · COMPLETED · sponsor: **Vascular Pharmaceuticals, Inc.** · enrollment: 165 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** VPI-2690B low dose
- **DRUG:** VPI-2690B medium dose
- **DRUG:** Placebo to match VPI-2690B
- **DRUG:** VPI-2690B high dose

## Key facts

- **NCT ID:** NCT02251067
- **Lead sponsor:** Vascular Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251067, "Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02251067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*